Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Copyright policy )Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
AbstractAmyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.
- Vrije Universiteit Brussel Belgium
- Wrocław Medical University Poland
- University of Lille France
- University of Paris-Saclay France
- Imperial College London United Kingdom
Neurologi, LD SCORE REGRESSION, Medizin, Cell Cycle Proteins, cerebrospinal fluid [Amyloid beta-Peptides], pathology [Alzheimer Disease], Medicine and Health Sciences, Pathology, GWAS, Cerebrospinal fuid, tau, Psychiatry, RISK, NEURODEGENERATION, ASSOCIATION, Alzheimer's disease, AMYLOID-BETA, amyloid-beta, Cerebrospinal fluid, Neurology, cerebrospinal fluid [Biomarkers], Amyloid-beta, Life Sciences & Biomedicine, Alzheimer’s disease, Alzheimer Disease/pathology; Amyloid beta-Peptides/cerebrospinal fluid; Apolipoproteins E/genetics; Biomarkers/cerebrospinal fluid; Cell Cycle Proteins; Humans; Peptide Fragments/cerebrospinal fluid; tau Proteins/cerebrospinal fluid; tau Proteins/genetics; Alzheimer’s disease; Amyloid-beta; Cerebrospinal fluid; GWAS; Tau, EXPRESSION, EADB consortium, Clinical Neurology, 610, tau Proteins, DIAGNOSIS, cerebrospinal fluid, Neurology and psychiatry, Apolipoproteins E, SDG 3 - Good Health and Well-being, Alzheimer Disease, 616, Humans, cerebrospinal fluid [Peptide Fragments], Original Paper, Science & Technology, Neurology & Neurosurgery, Amyloid beta-Peptides, MUTATIONS, ICTS (Institute of Clinical and Translational Sciences), Neurosciences, 1103 Clinical Sciences, GENE, Peptide Fragments, Biomedicine, genetics [tau Proteins], cerebrospinal fluid [tau Proteins], [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, TAU LEVELS, 3209 Neurosciences, genetics [Apolipoproteins E], GR@ACE study group, Human medicine, Neurosciences & Neurology, Tau, 1109 Neurosciences, Biomarkers, ddc: ddc:, ddc: ddc:610
Neurologi, LD SCORE REGRESSION, Medizin, Cell Cycle Proteins, cerebrospinal fluid [Amyloid beta-Peptides], pathology [Alzheimer Disease], Medicine and Health Sciences, Pathology, GWAS, Cerebrospinal fuid, tau, Psychiatry, RISK, NEURODEGENERATION, ASSOCIATION, Alzheimer's disease, AMYLOID-BETA, amyloid-beta, Cerebrospinal fluid, Neurology, cerebrospinal fluid [Biomarkers], Amyloid-beta, Life Sciences & Biomedicine, Alzheimer’s disease, Alzheimer Disease/pathology; Amyloid beta-Peptides/cerebrospinal fluid; Apolipoproteins E/genetics; Biomarkers/cerebrospinal fluid; Cell Cycle Proteins; Humans; Peptide Fragments/cerebrospinal fluid; tau Proteins/cerebrospinal fluid; tau Proteins/genetics; Alzheimer’s disease; Amyloid-beta; Cerebrospinal fluid; GWAS; Tau, EXPRESSION, EADB consortium, Clinical Neurology, 610, tau Proteins, DIAGNOSIS, cerebrospinal fluid, Neurology and psychiatry, Apolipoproteins E, SDG 3 - Good Health and Well-being, Alzheimer Disease, 616, Humans, cerebrospinal fluid [Peptide Fragments], Original Paper, Science & Technology, Neurology & Neurosurgery, Amyloid beta-Peptides, MUTATIONS, ICTS (Institute of Clinical and Translational Sciences), Neurosciences, 1103 Clinical Sciences, GENE, Peptide Fragments, Biomedicine, genetics [tau Proteins], cerebrospinal fluid [tau Proteins], [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, TAU LEVELS, 3209 Neurosciences, genetics [Apolipoproteins E], GR@ACE study group, Human medicine, Neurosciences & Neurology, Tau, 1109 Neurosciences, Biomarkers, ddc: ddc:, ddc: ddc:610
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).82 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!